T-cell alloimmunity and chronic allograft dysfunction.
Solid organ transplantation is the standard treatment to improve both the quality of life and survival in patients with various end-stage organ diseases. The primary barrier against successful transplantation is recipient alloimmunity and the need to be maintained on immunosuppressive therapies with associated side effects. Despite such treatments in renal transplantation, after death with a functioning graft, chronic allograft dysfunction (CAD) is the most common cause of late allograft loss. Recipient recognition of donor histocompatibility antigens, via direct, indirect, and semidirect pathways, is critically dependent on the antigen-presenting cell (APC) and elicits effector responses dominated by recipient T cells. In allograft rejection, the engagement of recipient and donor cells results in recruitment of T-helper (Th) cells of the Th1 and Th17 lineage to the graft. In cases in which the alloresponse is dominated by regulatory T cells (Tregs), rejection can be prevented and the allograft tolerated with minimum or no immunosuppression. Here, we review the pathways of allorecognition that underlie CAD and the T-cell effector phenotypes elicited as part of the alloresponse. Future therapies including depletion of donor-reactive lymphocytes, costimulation blockade, negative vaccination using dendritic cell subtypes, and Treg therapy are inferred from an understanding of these mechanisms of allograft rejection.
Medical Research Council Centre for Transplantation, King's College London, King's Health Partners, Guy's Hospital, London, UK.
Niloufar
N
Safinia
Behdad
B
Afzali
Kerem
K
Atalar
Giovanna
G
Lombardi
Robert I
RI
Lechler
D000818:Animals; D002908:Chronic Disease; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007519:Isoantigens / Q000276:immunology*; D007668:Kidney / Q000276:immunology* / Q000503:physiopathology; D007674:Kidney Diseases / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D016030:Kidney Transplantation / Q000009:adverse effects*; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007519:Isoantigens